Lipoprotein(a) in Chronic Renal Disease

Mineral and Electrolyte Metabolism

Volumn 22, Issue 1-3, 1996, Pages 16-21

  Stenvinkel, Peter ^a   Berglund, Lars ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Columbia University ^*  (United States)

Author keywords

Continuous ambulatory peritoneal dialysis; Hemodialysis; Lipoprotein(a); Nephrotic syndrome; Renal transplant recipients

Indexed keywords

ALBUMIN; LIPOPROTEIN A;

ATHEROSCLEROSIS; CHRONIC KIDNEY DISEASE; CONFERENCE PAPER; CONTROLLED STUDY; HEMODIALYSIS; HUMAN; KIDNEY TRANSPLANTATION; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RISK FACTOR;

ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; HUMANS; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LIPOPROTEIN(A); MORBIDITY; NEPHROTIC SYNDROME; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; RENAL DIALYSIS;

EID: 0029655606     PISSN: 03780392     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (67)

1. Berg K: A new serum type system in man-the Lp system. Acta Pathol Microbiol Scand 1963;59:369-382.
2. Utermann G: The mysteries of lipoprotein(a). Science 1989;246:904-910.
3. Dahlen GH, Guyton JR, Attar M, Farmer JA, Kautz JA, Gotto AM: Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation, 1986;74:758-765.
4. Scanu AM: Lipoprotein(a). A genetic risk factor for premature coronary heart disease. JAMA 1992;267:3326-3329.
5. Rosengren A, Wilhelmsen L, Eriksson E, Risberg B, Wedel H: Lipoprotein(a) and coronary heart disease: A prospective case-control study in a general population sample of middle-aged men. Br Med J 1990;301:1248-1251.
6. Armstrong VW, Cremer P, Eberle E, et al: The association between serum Lp(a) concentrations and angiographically-assessed coronary atherosclerosis: dependence on serum LDL levels. Atherosclerosis 1986;62:249-257.
7. McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM: cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987;300:132-137.
8. Lackner C, Boerwinkle E, Leffert CC, Rahmig T, Hobbs HH: Molecular basis of apolipoprotein(a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis. J Clin Invest 1991;87:2077-2086.
9. Gavish D, Azrolan N, Breslow JL: Plasma Lp(a) concentration is inversely correlated with the ratio of kringle IV/kringle V encoding domains in the apo(a) gene. J Clin Invest 1989;84:2021-2027.
10. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiens G, Hobb HH: Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest 1992;90:52-60.
11. Cressman MD, Heyka RJ, Paganini EP, O'Neil J, Skibinski CI, Hoff HF: Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 1992;86:475-482.
12. Kraft HG, Menzel HJ, Hopplicher F, Vogel W, Uterman G: Changes of genetic apoprotein phenotypes caused by liver transplantation. J Clin Invest 1989;83:137-142.
13. Krempler F, Kostner GM, Roscher A, Haslauser F, Bolzano K, Sandhofer F: Studies on the role of specific cell surface receptors in the removal of lipoprotein(a) in man. J Clin Invest 1983;71:1431-1441.
14. Miles LA, Plow EF: Lp(a) : An interloper in the fibrinolytic system. Thromb Haemost 1990;63:331-335.
15. Sandkamp M, Funke H, Schulte H, Köhler E, Assmann G: Lipoprotein(a) is an independent risk factor for myocardial infarction at a young age. Clin Chem 1990;1990;36:20-23.
16. Zenker G, Költringer P, Boné G, Niederkorn K, Pfeiffer K, Jürgens G: Lipoprotein(a) as a strong indicator for cerebrovascular disease. Stroke, 1986;17:942-945.
17. Rhoads GG, Dahlen G, Berg K, Morton NE, Dannenberg AL: Lp(a) lipoprotein as a risk factor for myocardial infarction. JAMA 1986;256:2540-2544.
18. Beisiegel U, Niendorf A, Wolf K, Reblin T, Rath M: Lipoprotein(a) in the arterial wall. Eur Heart J 1990;11(suppl E):174-183.
19. Cushing GL, Gaubatz JW, Nava ML, Burdick BJ, Bocan TMA, Guyton JR, Weilbaecher D, DeBakey HE, Lawrie GM, Morrisett JD: Quantitation and localization of apolipoproteins(a) and B in coronary artery bypass vein grafts resected at re-operation. Artheriosclerosis 1989;9:593-603.
20. Ridker PM, Hennekens CH, Stampfer MJ: A prospective study of lipoprotein(a) and risk of future myocardial infarction. JAMA 1993;270:2195-2199.
21. Schaefer EJ, Lamon-Fava S, Jenner JL, McNamara JR, Ordovas JM, Davis E, Abolafia JM, Lippel K, Levy RI: Lipoprotein(a) levels and risk of coronary heart disease in men: The lipid research clinics coronary primary prevention trial. JAMA 1994;271:999-1008.
22. Karádi I, Romics L, Pálos G, Domán J, Kaszás I, Hesz À, Kostner GM: Lp(a) lipoprotein concentration in serum of patients with heavy proteinuria of different origin. Clin Chem 1989;35:2121-2123.
23. Stenvinkel P, Berglund L, Heimbürger O, Pettersson E, Alvestrand A: Lipoprotein(a) in nephrotic syndrome. Kidney Int 1993;44:1116-1123.
24. Short CD, Durrington PN, Mallick NP, Bhatnagar D, Hunt LP, MBewu A: Serum lipoprotein(a) in men with proteinuria due to idiopathic membranous nephropathy. Nephrol Dial Transplant 1992;(suppl 1):109-113.
25. Fujita T, Saito E, Ohi H, Yasugi T, Hatano M: Lipoprotein(a) predicts the risk of thrombogenic complications in nephrotic syndrome. Nephron 1992;61:122.
26. Wanner C, Rader D, Bartens W, Krämer J, Brewer B, Schollmeyer P, Wieland H: Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome. Ann Intern Med 1993;119:263-269.
27. Faucher C, Douchet C, Baumelou A, Chapman J, Jacobs C, Thillet J: Elevated lipoprotein(a) levels in primary nephrotic syndrome. Am J Kidney Dis 1993;22:808-813.
28. Thomas ME, Freestone A, Varghese Z, Persaud TW, Moorhead JF: Lipoprotein(a) in patients with proteinuria. Nephrol Dial Transplant, 1992;7:597-601.
29. Gansevoort RT, Heeg JE, Dikkeschei FD, de Zeeuv D, de Jong PE, Dullaart RPF: Symptomatic antiproteinuric treatment decreases serum lipoprotein(a) concentration in patients with glomerular proteinuria. Nephrol Dial Transplant 1994;9:244-250.
30. Davies RW, Staprans I, Hutchison FN, Kaysen GA: Proteinuria, not altered albumin metabolism, affects hyperlipidemia in the nephrotic syndrome. J Clin Invest 1990;86:600-605.
31. Ordonez JD, Hiat R, Killebrew E, Fireman B: The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int 1993;44:638-642.
32. Keane WF, Kasiske BL, O'Donnel MD: Lipids and progressive glomerulosclerosis. Am J Nephrol 1988;8:261-271.
33. Rostand SG, Kirk KA, Rutsky EA: Relationship of coronary risk factors to hemodialysis-associated ischemic heart disease. Kidney Int 1982;22:304-308.
34. Broyer M, Brunner FP, Brynger H, Fassbinder W, Guillou PJ, Oules R, Rizzoni G, Selwood NH, Wing AJ, Challah S, Dykes SR: Demography of dialysis and transplantation in Europe 1984. Nephrol Dial Transplant 1986;1:1-8.
35. Goldberg AP, Harter HR, Patsch W, Schechtman KB, Province M, Weerts C, Kuisk I, McCrate MM, Schonfeld G: Racial differences in plasma high-density lipoproteins in patients receiving hemodialysis: A possible mechanism for accelerated atherosclerosis in white men. N Engl J Med 1983;308:1245-1252.
36. Parra HJ, Mezdour H, Cachera C, Dracon M, Tacquet A, Fruchart JC: Lp(a) lipoprotein in patients with chronic renal failure treated by hemodialysis. Clin Chem 1987;33:721.
37. Auguet T, Sentí M, Rubíes-Prat J, Pelegrí A, Pedro-Botet J, Nogués X, Romero R: Serum lipoprotein(a) in patients with chronic renal failure receiving hemodialysis: influence of apolipoprotein(a) genetic polymorphism. Nephrol Dial Transplant 1993;8:1099-1103.
38. Webb AT, Reaveley A, O'Donnell M, O,Connor B, Seed M, Brown EA: Lipoprotein(a) in patients on maintenance hemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 1993;8:609-613.
39. Shoji T, Nishizawa Y, Nishitani H, Yamakawa M, Morii H: High serum lipoprotein(a) concentrations in uremic patients treated with continuous ambulatory peritoneal dialysis. Clin Nephrol 1992;38:271-276.
40. Goldwasser P, Michel M-A, Collier J, Mittman N, Fein PA, Gusik S-A, Avram MM: Prealbumin and lipoprotein(a) in hemodialysis: Relationships with patient and vascular access survival. Am J Kidney Dis 1993;22:215-225.
41. Hirata K, Kikuchi S, Saku K, Jimi S, Zhang B, Naito S, Hamaguchi H, Arakawa K: Apolipoprotein(a) phenotypes and serum lipoprotein(a) levels in maintenance hemodialysis patients with/without diabetes mellitus. Kidney Int 1993;44:1062-1070.
42. Okura Y, Saku K, Hirata K, Zhang B, Liu R, Ogahara S, Naito S, Kajiyama G, Arakawa K: Serum lipoprotein(a) levels in maintenance hemodialysis patients. Nephron 1993;65:46-50.
43. Buggy D, Breathnach A, Keogh B, Cooke T, Feely J: Lipoprotein(a) and treatment of chronic renal disease. J Intern Med 1993;234:453-455.
44. Irish AB, Simons LA, Savdie E, Hayes JM, Simons J: Lipoprotein(a) levels in chronic renal disease states dialysis and transplantation. Aust NZ J Med 1992;22:243-248.
45. Ross EA, Shah GM, Gupta AK, Kashyap ML: Elevated lipoprotein(a) in peritoneal dialysis patients (abstract). J Am Soc Nephrol 1992;3:418.
46. Petersen LJ; Ringsdal V, Ladefoged SD, Hansen PR, Wick A: Lipoprotein(a) as an independent risk factor for cardiovascular disease in dialysis patients (abstract). Periton Dial Int 1994;14:S15.
47. Heimbürger O, Stenvinkel P, Berglund L, Tranaeus A, Lindholm B: Increased plasma lipoprotein(a) in CAPD is related to peritoneal transport of proteins and glucose. In presss, Nephron.
48. Yang WS, Kim SB, Min WK, Park S, Mong CD, Park JS: Atherogenic lipid profile and lipoprotein(a) in relation to serum albumin in haemodialysis patients. Nephrol Dial Transplant 1995;10:1668-1671.
49. del Cura J, Gil-Parasio A, Borque L, Carazo M-E, Maside C, Sánchez-Casajús A: Lipoprotein(a) in chronic renal failure patients undergoing hemodialysis: Does it have an independent role in the development of further cardiovascular complications? Nephron 1993;65:644-645.
50. Wiklund O, Angelin B, Olofsson SO, Eriksson M, Fager G, Berglund L, Bondjers G: Apolipoprotein(a) and ischemic heart disease in familial hypercholesterolemia. Lancet 1990;335:1360-1363.
51. Kandoussi A, Cachera C, Pagniez D, Dragon M, Fruchart JC, Tacquet A: Plasma level of lipoprotein Lp(a) is high in predialysis or hemodialysis, but not in CAPD. Kidney Int 1992;42:424-425.
52. Anwar N, Bhatnagar D, Short CD, Mackness MI, Durrington PN, Prais H, Gokal R: Serum lipoprotein(a) concentrations in patients undergoing continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 1993;8:71-74.
53. Thillet J, Faucher C, Issad B, Allouache M, Chapman J, Jacobs C: Lipoprotein(a) in patients treated by continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1993;22:226-232.
54. Murphy BG, McNamee P, Duly E, Henry W, Arcbold P, Trinick T: Increased serum apolipoprotein(a) in patients with chronic renal failure treated with continuous ambulatory peritoneal dialysis. Atherosclerosis 1992;93:53-57.
55. Barbagallo CM, Averna MR, Sparacino V, Galione A, Caputo F, Scafidi V, Amato S, Mancino C, Cefalú AB, Notarbartolo A: Lipoprotein(a) levels in end-stage renal failure and renal transplantation. Nephron, 1993;64:560-564.
56. Maiorca R, Cancarini GC, Brunori G, Camerini C, Manili L: Morbidity and mortality of CAPD and hemodialysis. Kidney Int 1993;43:S4-S15.
57. Tranaeus A, Heimbürger O, Lindholm B, Bergström J: Six years' experience of CAPD at one centre: A survey of major findings. Periton Dial Int 1988;8:31-41.
58. Brunner FP, Broyer M, Brynger H, et al: Survival on renal replacement therapy: Data from the EDTA Registry. Nephrol Dial Transplant 1988;2:109-122.
59. Kasiske BL: Risk factors for accelerated atherosclerosis in renal transplant recipients. Am J Med 1988;84:985-992.
60. Black IW, Wilcken DEL: Decreases in apoprotein(a) after renal transplantation: Implications for lipoprotein(a) metabolism. Clin Chem 1992;38:353-357.
61. Hörkkö S, Huttunen K, Kervinen K, Antero Kesäniemi Y: Decreased clearance of uremic and mildly carbamylated low-density lipoprotein. Eur J Clin Invest 1994;24:105-113.
62. Kaiske BL, Tortorice KL, Heim-Duthoy KL, Goryance JM, Venkateswara RK: Lovastatin treatment of hypercholesterolemia in renal transplant recipients. Transplantation 1990;49:95-100.
63. Webb AT, Plant M, Reaveley DA, O'Donnell M, Luck VA, O'Connor B, Seed M, Brown EA: Lipid and lipoprotein(a) concentrations in renal transplant patients. Nephrol Dial Transplant 1992;7:636-641.
64. Heimann P, Josephson, MA, Fellner SK, Thistlethwaite JC, Stuart FP, Dasgupta A: Elevated lipoprotein(a) levels in renal transplantation and hemodialysis patients. Am J Nephrol 1991;11:470-474.
65. Segarra A, Chacón P, Vilardell M, Piera LL: Cyclosporin and serum lipids in renal transplant recipients. Lancet 1993;341-766.
66. Webb AT, Reaveley DA, O'Donnell M, O'Connor B, Seed M, Brown EA: Does cyclosporine increase lipoprotein(a) concentrations in renal transplant recipients? Lancet 1993;341:268-270.
67. Dieplinger H, Lackner C, Kronenberg F, Sandholzer C, Lhotta K, Hoppichler F, Graf H, Köning P: Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a). J Clin Invest 1993;91:397-401.